The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.
 
Nathan A. Pennell
Consulting or Advisory Role - AstraZeneca; Lilly; Regeneron
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech (Inst); Merck; Newlink Genetics (Inst); Pfizer (Inst)
 
Alex Mutebi
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Zheng-Yi Zhou
Consulting or Advisory Role - Novartis (Inst)
 
Marie Louise Ricculli
Consulting or Advisory Role - Novartis (Inst)
 
Wenxi Tang
Consulting or Advisory Role - Novartis (Inst)
 
Helen Wang
Consulting or Advisory Role - Novartis (Inst)
 
Annie Guerin
Consulting or Advisory Role - Novartis (Inst)
 
Tom Arnhart
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Kenneth W. Culver
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Gregory Alan Otterson
Consulting or Advisory Role - Amgen (Inst); Merck (Inst); Novartis (Inst); Takeda (Inst)
Research Funding - Acerta Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Ignyta (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)